Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Imported fever and malaria

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Falciparum malaria or high-consequence infection

Fever after tropical travel is malaria until urgent testing shows otherwise. Impaired consciousness, seizure, prostration, respiratory distress, shock, hypoglycaemia, severe anaemia or more than 2% parasitaemia in a child indicates severe or complicated malaria. Certain itinerary and exposure combinations also require a viral-haemorrhagic-fever pathway before routine contact and sampling.

Action: Stabilise airway, breathing, circulation and glucose; alert senior paediatrics, infection or tropical medicine and the laboratory immediately. Take urgent EDTA blood for films and an adjunct rapid test without waiting for a fever spike. Treat severe malaria promptly with intravenous artesunate under the current national specialist protocol and cover bacterial sepsis when clinically indicated. If epidemiology raises a high-consequence infection, isolate and obtain health-protection advice before unprotected examination or routine specimen processing.

Synopsis

Assess a febrile child after international travel without missing falciparum malaria, severe imported infection or a high-consequence exposure, while also recognising that common childhood infections remain common.

  • Ask about fever after travel before anchoring on a familiar diagnosis: exact countries and regions, dates, transit, rural or urban stay and reason for travel change the differential.
  • UKHSA advises considering malaria in every ill traveller returning from the tropics during the previous year, especially the previous 3 months; prophylaxis does not exclude it.
  • Reference-standard testing is urgent thick and thin blood-film microscopy. Send EDTA venous blood labelled ‘Urgent, suspected malaria’ so it reaches the laboratory within 1 hour.
  • Do not wait for a fever spike. Falciparum fever is often irregular, and delay allows parasitaemia and organ dysfunction to progress over hours.
  • A rapid diagnostic test is an adjunct, not a replacement for microscopy. One negative film or rapid test does not exclude malaria.
  • If suspicion persists, examine blood films daily for 3 days while investigating other causes; seek tropical or infection advice when all are negative but malaria remains plausible.
  • Assess severity at the same time as diagnosis: consciousness, seizures, ability to sit or stand, respiratory effort, perfusion, urine output, glucose, acid-base state, haemoglobin and parasitaemia.
  • Treat severe malaria immediately with intravenous artesunate under specialist guidance; do not delay for final species identification, reference-laboratory confirmation or a second film.
  • Take blood cultures and assess bacterial sepsis because malaria can coexist with bacterial infection and an apparent travel diagnosis does not remove ordinary paediatric risk.
  • Enteric fever, dengue, rickettsial disease, leptospirosis, viral hepatitis and common respiratory, urinary and gastrointestinal infections are important alternatives guided by incubation and exposure.
  • Before routine sampling, check whether travel and exposure meet the current national viral-haemorrhagic-fever or other high-consequence-infection pathway and involve infection control and health protection.
  • Malaria is notifiable. Confirm treatment, species, clearance plan, delayed haemolysis follow-up after artesunate and prevention advice with an experienced infection or tropical team.

Key red flags

Any unwell child who has returned from a malaria-endemic area within the previous year needs urgent malaria consideration, particularly when travel was within 3 months.

Altered consciousness, repeated seizure, inability to sit or stand, respiratory distress, acidosis, shock or oliguria suggests severe malaria or another critical infection.

Check bedside glucose immediately because malaria, sepsis, poor intake and quinine treatment can each cause dangerous hypoglycaemia.

Severe pallor, jaundice, haemoglobinuria, bleeding, hepatosplenomegaly or rapidly falling haemoglobin or platelets needs urgent senior and haematology-informed care.

Fever plus relevant travel, healthcare, animal, funeral or sick-contact exposure may meet a viral-haemorrhagic-fever risk definition; use the current national pathway before routine handling.

An infant, immunocompromised child, child with sickle cell disease or child without a functioning spleen can deteriorate rapidly and warrants a lower admission threshold.

A petechial or purpuric rash, meningism, severe abdominal pain, persistent vomiting or clinical shock must trigger parallel assessment for meningococcal disease, sepsis and surgical causes.

Investigation priorities

01
Reference standard: thick and thin blood filmsFirst stepReference standard

Detect parasites, identify species, quantify parasitaemia and monitor response.

Management branches

First hourTest for malaria while stabilising

A child is unwell after travel to a malaria-risk area within the previous year.

  1. Assess ABCDE, consciousness, perfusion and bedside glucose, obtain IV or IO access when indicated and call senior paediatric and infection support.
  2. Send an EDTA venous sample marked ‘Urgent, suspected malaria’ for immediate thick and thin films plus an adjunct rapid test, without waiting for a fever spike.
  3. Take cultures and severity bloods, treat shock, hypoglycaemia, seizures and suspected bacterial sepsis, and decide monitored or critical-care placement from physiology.

Key medicines

Intravenous artesunateFor severe or complicated malaria, start the current national weight-based intravenous artesunate regimen immediately under paediatric infection or tropical-medicine supervision, then complete an effective oral antimalarial course once clinically and parasitologically appropriate.Do not delay for final speciation or reference confirmation. Use critical-care monitoring, check glucose and parasite clearance, and arrange blood count and haemolysis surveillance for 4 weeks because delayed post-artesunate haemolysis can occur.
Atovaquone with proguanilFor specialist-selected acute uncomplicated falciparum malaria, give once daily for 3 days with food or a milky drink: 5–8 kg two paediatric tablets; 9–10 kg three paediatric tablets; 11–20 kg one adult-strength tablet; 21–30 kg two; 31–40 kg three; over 40 kg four.The paediatric tablet contains 62.5 mg/25 mg and adult tablet 250 mg/100 mg. Repeat a dose vomited within 1 hour and seek advice if vomiting recurs. It is not treatment for severe malaria; check renal function and product contraindications.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • UKHSA malaria diagnosis guidance 2026Emergency recognition, urgent sample handling, microscopy, rapid-test limitations, serial films and notification.
  • UKHSA malaria awareness and severe featuresClinical presentation and major features of severe or complicated malaria in children.
  • British Infection Association published guidelinesNational specialist malaria-treatment and returning-traveller guideline index.
  • Malarone paediatric SmPCLicensed tablet strength, weight bands, administration, vomiting and safety information.
  • Malarone adult-strength SmPCWeight-banded treatment of acute uncomplicated falciparum malaria above 10 kg.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom